Dominion Energy Inc vs Summit Therapeutics Inc — how do they compare? Dominion Energy Inc trades at $68.08 (market cap $59.90B), while Summit Therapeutics Inc trades at $15.4 (market cap $12.06B). The key difference: Dominion Energy Inc is far larger — about 5× Summit Therapeutics Inc's market cap, and Dominion Energy Inc pays a 3.92% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| D | SMMT | |
|---|---|---|
Market Cap | $59.90B | $12.06B |
Sector | Utilities | Health |
52-Week High | $71.67 | $26.98 |
52-Week Low | $57.08 | $12.55 |
Enterprise Value | $114.01B | $11.39B |
Dividend Yield | 3.92% | — |
Signals from Pluang's Aura AI — not financial advice
Dominion Energy (D) trades at $67.14, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with Q2 2026 EPS beating estimates at $0.79 versus $0.681 expected, and revenue growth to $16.51B in 2025. Analysts maintain a consensus price target of $70.43, with 34% buy ratings. Recent news highlights data center demand driving performance, though merger speculation with NextEra introduces uncertainty.
Outlook remains cautiously optimistic given earnings beats and dividend consistency, but risks include high debt levels and potential regulatory pressures. The stock offers steady income with a $0.67 quarterly dividend, yet investors should weigh execution risks against growth from energy infrastructure demands.
No Aura AI signal available yet.
Trailing returns across standard periods
Based in Richmond, Virginia, Dominion Energy is an integrated energy company with over 30 gigawatts of electric generation capacity and more than 90,000 miles of electric transmission and distribution lines. Dominion owns a liquefied natural gas export facility in Maryland and is constructing a 5.2 GW wind farm off the Virginia Beach coast.
Read more on D →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →